HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir

Antiviral Therapy

Volumn 19, Issue 6, 2014, Pages 579-586

  Bunupuradah, Torsak ^a   Bowonwattanuwong, Chureeratana ^b   Jirajariyavej, Supunnee ^c   Munsakul, Warangkana ^d   Klinbuayaem, Virat ^e   Sophonphan, Jiratchaya ^a   Mahanontharit, Apicha ^a   Hirschel, Bernard ^f   Ruxrungtham, Kiat ^g   Ananworanich, Jintanat ^a,g,h  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHONBURI HOSPITAL   (Thailand)

^c Taksin Hospital   (Thailand)

^d NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^e Sanpatong Hospital   (Thailand)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; LOPINAVIR; PHOSPHONIC ACID DERIVATIVE; RITONAVIR; TENOFOVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; BODILY SECRETIONS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENITAL TRACT INFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; TABLET; TREATMENT DURATION; VAGINA SMEAR; VIREMIA; VIRUS SHEDDING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PHYSIOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; GENITALIA; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LOPINAVIR; MALE; ORGANOPHOSPHONATES; RISK FACTORS; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS SHEDDING;

EID: 84920196082     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2737     Document Type: Article

References (33)

1. Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 2003; 5:3-18.
2. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3:27-35.
3. Ghosn J, Viard JP, Katlama C, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18:447-457.
4. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res 2003; 1:69-86.
5. Ananworanich J, Kerr SJ, Vernazza P, et al. Genital shedding of HIV after scheduled treatment interruption. Int J STD AIDS 2011; 22:61-66.
6. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
7. Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A. Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? AIDS Rev 2010; 12:127-134.
8. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
9. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.
10. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
11. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 2012; 17:1351-1361.
12. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961.
13. Ghosn J, Chaix ML, Peytavin G, et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61:1344-1347.
14. Launay O, Tod M, Louchahi K, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004; 48:632-634.
15. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21:1309-1315.
16. Lambert-Niclot S, Peytavin G, Duvivier C, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54:4910-4913.
17. Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS 2012; 26:1535-1543.
18. Gutmann C, Cusini A, Gunthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24:2347-2354.
19. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814.
20. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601.
21. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497.
22. Venkatesh KK, Delong AK, Kantor R, et al. Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load. J Womens Health 2013; 22:330-338.
23. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
24. Vernazza P, Hirschel B, Bernasconi E, Fiepp M. HIV-infected patients under HAART without any other sexually transmitted infection do not transmit HIV by sexual intercourse. Bull Med Suisses 2008; 89:165-169.
25. Nosyk B, Audoin B, Beyrer C, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS 2013; 27:1159-1165.
26. Ndziessi G, Cohen J, Kouanfack C, et al. Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial). PLoS ONE 2013; 8:e62611.
27. Hasse B, Ledergerber B, Hirschel B, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2010; 51:1314-1322.
28. Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 2012; 26:971-975.
29. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 2010; 24:2733-2737.
30. Anderson BL, Wang CC, Delong AK, et al. Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis 2008; 47:1216-1221.
31. Pasquier C, Anderson D, Andreutti-Zaugg C, et al. Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. J Med Virol 2006; 78:877-882.
32. Pasquier C, Andreutti C, Bertrand E, et al. Multicenter assessment of HIV-1 RNA quantitation in semen in the CREAThE network. J Med Virol 2012; 84:183-187.
33. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS 2000; 14:2101-2107.